(lp0
S'Could Rexahn Pharmaceuticals Have Something? Seeking Alpha - 18 hours ago Rexahn Pharmaceuticals, Inc.  is a clinical stage biotechnology company dedicated to targeting specific proteins localized in human cancer cells but not in healthy tissues for the treatment of cancer.Home Health Care Rexahn Pharmaceuticals, Inc  Goes Public To ... - Journal TranscriptRexahn Pharmaceuticals, Inc. performed Poor with a change of -26.14% in the ... - Free Observer'
p1
aS"Rexahn Pharmaceuticals Inc  Is Splitting, But We're Still Bullish Insider Financial - Apr 14, 2017 At the end of March, we asked the question 'Can Rexahn Pharmaceuticals, Inc.  Continue To Run?' as part of this piece.Rexahn Pharmaceuticals, Inc.  Announces 1-for-10 Reverse Stock Split - Smarter AnalystRexahn Announces 1-for-10 Reverse Stock Split - GlobeNewswire "
p2
aS'Rexahn Pharmaceuticals Inc  Continues To Shine Against A Backdrop ... Insider Financial - Mar 28, 2017 Early March, we said that readers should keep an eye on Rexahn Pharmaceuticals, Inc.  as 2017 matures. The company had basically run flat throughout January, and then took a little jump during February.Rexahn Pharmaceuticals, Inc. surged in the Previous Trading Session with the ... - Free ObserverAnalytical Guide for Rexahn Pharmaceuticals, Inc. , Trevena, Inc. (TRVN ... - The USA Commerce'
p3
aS'This Analyst Sees Over 200% Upside For Rexahn Pharmaceuticals, Inc.  Shares Smarter Analyst - Apr 6, 2017 In a research report issued Thursday, H.C. Wainwright analyst Joseph Pantginis assumed coverage on shares of Rexahn Pharmaceuticals, Inc.  with a Buy rating and a $2.00 price target, which implies an upside of over 200% from current&nbsp;...'
p4
aS'Rodman &amp; Renshaw Assumes Rexahn Pharmaceuticals Inc.  at Buy StreetInsider.com - Apr 6, 2017 Rodman &amp; Renshaw assumes overage on Rexahn Pharmaceuticals Inc.  with a Buy rating and a price target of $2.00.'
p5
aS'The Technicals For Rexahn Pharmaceuticals, Inc.  Tell An Interesting Tale NY Stock News - Apr 11, 2017 The technicals for Rexahn Pharmaceuticals, Inc.  have taken shape, and with them a comprehensive picture has emerged.'
p6
aS'Trading Scope: Indicator Review for Rexahn Pharmaceuticals Inc  Rives Journal - 15 hours ago Narrowing in on moving averages for Rexahn Pharmaceuticals Inc , the 200-day is at 0.25, the 50-day is 0.38, and the 7-day is resting at 0.59.'
p7
aS'Stock to Watch: Rexahn Pharmaceuticals, Inc.  Benton Bulletin - 13 hours ago Rexahn Pharmaceuticals, Inc.  presently has a Piotroski F-Score of 2. The goal of the F-Score is to help locate companies with strengthening balance sheets, and to weed out poor performers.'
p8
aS'Experts proposition on the searing stocks: Rexahn Pharmaceuticals, Inc. (RNN ... The USA Commerce - 21 hours ago On the close of 04/13/2017 Rexahn Pharmaceuticals, Inc.  dropped -26.14% to hit $0.46. During the session shares stayed in the range from $0.560 to $0.382.'
p9
aS'Rexahn Pharmaceuticals, Inc.  Continues Its Vertical Trajectory StockNewsUnion - Apr 3, 2017 Rexahn Pharmaceuticals, Inc.  hit a YTD low of $0.14 on January 4, 2017. But since then RNN shares have been on a tear and today hit an inter-day high of $0.58 - a 240% gain from its $0.14 low.Rexahn Pharmaceuticals, Inc.  has a 52-Week High of $0.56 - StandardOracleRexahn Pharmaceuticals, Inc. closed with a change of 5.81% in the Previous ... - Free Observer'
p10
a.